<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Crystallographic analysis of the full-length glutamate receptor agonist-binding domain</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">J</forename><surname>Mccarthy</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max Planck Institute for Medical Research</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Dean</forename><surname>Madden</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max Planck Institute for Medical Research</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Laure</forename><surname>Delarbre</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max Planck Institute for Medical Research</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Eckhard</forename><surname>Hofmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max Planck Institute for Medical Research</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Crystallographic analysis of the full-length glutamate receptor agonist-binding domain</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">DD2945B8A2A894FA0D85D3CB9C24A9CA</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-05-22T16:00+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">unknown</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=1, consolidateHeader=1, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=true, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>LS-1892</keywords>
			</textClass>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p>Glutamate receptors located in the post-synaptic membranes of neuronal cells are the primary mediators of excitatory synaptic signals in the central nervous system. A soluble ligandbinding domain (called S1S2) can be separately expressed in recombinant form and retain its full ligand-binding activity and pharmacological selectivity (1). Atomic resolution structures of a truncated version of S1S2 have been reported in the apo form and in complex with various ligands (2, 3). These structures showed a clear conformational change associated with agonist binding. The coupling between these changes and gating of the ion channel is mediated by peptides that connect S1S2 to the receptor's transmembrane domains; these peptides were omitted from the truncated S1S2 construct. The peptides are known to influence activation and desensitization in the intact receptor (4-6) and constitute ca. 20% of the molecular mass of the domain. In a previous experiment (LS1751), we collected a 3.2 Å resolution native dataset on P2 1 2 1 2 crystals (unit cell: 96.9 x 176.5 x 87.6 Å) of a "fulllength" S1S2 construct containing these peptides. These crystals yielded a molecular replacement solution, using the core domain structure as a search model. The domains pack as NCS-related dimers, and the dimers then interact via the connecting peptides (manuscript in preparation). This interaction may mimic the "dimer of dimers" association that has been postulated for the channels (8). To improve the definition of the connecting peptides' electron density, we have sought heavy-atom derivatives of the full-length crystals. In addition, we know from stopped-flow experiments (7) that ligands dock in the open binding site before conformational change occurs. We have now captured conformational intermediates that reveal the initial docking sites of ligands to the empty binding site.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Measurements were performed on heavy-atom soaked crystals that had been screened for diffraction quality during LS-1751, but could not be collected due to an optics failure. 5 datasets were collected between 2.9 and 3.5 Å resolution, but none were derivatized (see Table ). Datasets were also collected from 3 docking intermediate complexes: apo-S1S2 crystals were flash-cooled after brief soaks in saturating concentrations of the antagonists CNQX and NBQX (neither have been structurally characterized) and of the partial agonist kainate. Complexes with the physiological agonist glutamate did not exhibit high-resolution diffraction. Phases were established for all complexes using molecular replacement with the published structure of the GluRB binding domain core (1FTO; ref.</p><p>3). The NBQX-soaked crystal form did not reveal difference density at the binding site for ligand, but the soaks with CNQX and kainate did. Refinement of these structures is currently underway.  </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc>Armstrong N. &amp; Gouaux E. (2000) Neuron 28:165; 4. Krupp, J.J., et al. (1998) Neuron 20: 317; 5. Villarroel, A., et al. (1998) Neuron 20: 329; 6. Sommer, B., et al. (1990) Science 249: 1580; 7.Abele, R. et al. (2000) J. Biol. Chem. 275: 21355; 8. Ayalon, G. &amp; Stern-Bach, Y. (2001) Neuron 13:103.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 :</head><label>1</label><figDesc>GluRB data sets collected during LS-1892</figDesc><table><row><cell>Data set</cell><cell>Soak</cell><cell>Res.</cell><cell>R merge</cell><cell cols="2">&lt;I&gt;/&lt;σ I &gt; Compl.</cell><cell>Aim</cell><cell>Result</cell></row><row><cell></cell><cell></cell><cell>( )</cell><cell>(%)</cell><cell></cell><cell>(%)</cell><cell></cell><cell></cell></row><row><cell>443c4ag</cell><cell>10 mM</cell><cell>3.4</cell><cell>15.3</cell><cell>7.9 (2.5)</cell><cell>79.8</cell><cell>MIR phases</cell><cell>No</cell></row><row><cell></cell><cell>AgNO 3 (48h)</cell><cell></cell><cell>(53.4)</cell><cell></cell><cell>(63.3)</cell><cell></cell><cell>derivative</cell></row><row><cell>440eu</cell><cell>10 mM Eu 3+</cell><cell>2.9</cell><cell>10.6</cell><cell>10.4 (2.2)</cell><cell>90.7</cell><cell>MIR phases</cell><cell>No</cell></row><row><cell></cell><cell>(2 min)</cell><cell></cell><cell>(60.4)</cell><cell></cell><cell>(94.7)</cell><cell></cell><cell>derivative</cell></row><row><cell>444a1osa</cell><cell>10 mM</cell><cell>3.2</cell><cell>7.5</cell><cell>12.3 (2.4)</cell><cell>86.7</cell><cell>MIR phases</cell><cell>No</cell></row><row><cell></cell><cell>OsBr 6 (5h)</cell><cell></cell><cell>(55.5)</cell><cell></cell><cell>(97.5)</cell><cell></cell><cell>derivative</cell></row><row><cell>443c4urb</cell><cell>1% UO 2 +</cell><cell>3.2</cell><cell>19.0</cell><cell>8.3 (1.9)</cell><cell>85.9</cell><cell>MIR phases</cell><cell>No</cell></row><row><cell></cell><cell>(2h)</cell><cell></cell><cell>(91.2)</cell><cell></cell><cell>(96.3)</cell><cell></cell><cell>derivative</cell></row><row><cell>430b6xe</cell><cell>3 bars xenon</cell><cell>3.5</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>MIR phases</cell><cell>Poor</cell></row><row><cell></cell><cell>(20 min)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>quality</cell></row><row><cell>421kab</cell><cell>1 mM</cell><cell>3.3</cell><cell>11.0</cell><cell>9.7 (3.1)</cell><cell>87.5</cell><cell>Intermediate</cell><cell>Under</cell></row><row><cell></cell><cell>kainate (10</cell><cell></cell><cell>(40.5)</cell><cell></cell><cell>(68.2)</cell><cell>agonist-</cell><cell>refinement</cell></row><row><cell></cell><cell>min)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>bound</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>conformation</cell><cell></cell></row><row><cell>502b55</cell><cell>0.1 M</cell><cell>3.3</cell><cell>14.3</cell><cell>7.9 (3.11)</cell><cell>88.1</cell><cell>Antagonist-</cell><cell>No NBQX</cell></row><row><cell></cell><cell>NBQX (40</cell><cell></cell><cell>(50.4)</cell><cell></cell><cell>(71.0)</cell><cell>bound</cell><cell>bound</cell></row><row><cell></cell><cell>min)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>structure</cell><cell></cell></row><row><cell>421cna</cell><cell>1 mM</cell><cell>3.4</cell><cell>13.8</cell><cell>9.9 (3.6)</cell><cell>85.9</cell><cell>Antagonist-</cell><cell>Under</cell></row><row><cell></cell><cell>CNQX (25</cell><cell></cell><cell>(42.8)</cell><cell></cell><cell>(66.6)</cell><cell>bound</cell><cell>refinement</cell></row><row><cell></cell><cell>min)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>structure</cell><cell></cell></row></table><note><p>1.Kuusinen, A. et al. (1995)  </p><p>EMBO J. 14:6327); 2. Armstrong N. et al. (1998) Nature 395:913; 3.</p></note></figure>
		</body>
		<back>
			<div type="references">

				<listBibl/>
			</div>
		</back>
	</text>
</TEI>
